Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic
Wiener klinische Wochenschrift · 2025
DOI: 10.1007/s00508-024-02465-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Seungjune Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal, Registries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
The development of monoclonal anti-amyloid antibodies, a disease-modifying treatment for Alzheimer’s disease (AD), has raised the necessity to identify the epidemiological profile of the possible target patients who would benefit from such therapy. These are patients in the early stages of AD with biomarker-confirmed brain amyloid positivity. In this study, the epidemiological profile of possible target patients in Austria and Vienna was estimated. The number of patients in the stage of amyloid-beta (Aβ)-positive prodromal AD in Austria and Vienna are 193,500 and 34,700 patients, respectively. The expected patient demand for the upcoming therapy in Austria and Vienna are 61,200 and 11,100 patients, respectively. In the memory clinic of the Vienna General Hospital, the number of treatment-eligible patients for an upcoming anti-amyloid antibody was on average 52.8 patients per year, which is about 10% of the total number of patients visiting the memory clinic every year. Several challenges to provide therapy to the general population include expanding the MCI screening in primary care and increasing the capacity of the healthcare system for biomarker testing, infusion delivery, and ARIA management. The study primarily addresses the status quo of identifying patients on memory clinics through cognitive screening and biomarker testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria.
- Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria. elisabeth.stoegmann@meduniwien.ac.at.
Förderung
- Medical University of Vienna
Zitieren
APA
Lee, S., & Stögmann, E. (2025). Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-024-02465-8
Vancouver
Lee S, Stögmann E. Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-024-02465-8
BibTeX
@article{Lee2025,
author = {Lee, Seungjune and Stögmann, Elisabeth},
title = {Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic},
journal = {Wiener klinische Wochenschrift},
year = {2025},
doi = {10.1007/s00508-024-02465-8}
}
EUVIMED